Outpatient Treatment With Anti-Coronavirus Immunoglobulin
- Conditions
- COVIDSARS-CoV2 InfectionCovid19
- Interventions
- Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)Other: Placebo
- Registration Number
- NCT04910269
- Lead Sponsor
- University of Minnesota
- Brief Summary
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo.
1. Asymptomatic and no limitations in usual activity due to COVID-19
2. Mild COVID-19 illness or minor limitations to usual activity
3. Moderate COVID-19 illness and with major limitations to usual activity
4. Severe COVID-19 or serious disease manifestation from COVID-19
5. Critical illness from COVID-19 or Death
Two strata of participants will be identified for analysis purposes. Stratum 2 will be participants who receive direct-acting antivirals (DAAs) or other anti-SARS-CoV2 agents that are approved/available and recommended for use as part of standard of care (SOC), estimated to be about 20% of participants. Stratum 1 will be participants who do not receive this agents, estimated to be about 80% of participants.
- Detailed Description
The primary objective will be addressed by testing two hypotheses aimed at assessing whether hIVIG + standard of care (SOC) is superior to placebo + SOC for the primary ordinal endpoint at Day 7. These hypotheses will be tested for the following two groups: a) among all randomized participants (stratum 1 and 2), and b) among only participants enrolled in stratum 1. For the primary analysis, overall type 1 error will be controlled at 5% by using a 2-sided significance level of 0.035 for each hypothesis. This significance level was obtained using the correlation between the test statistics for the proportional log odds ratio for all randomized participants and for this log odds ratio for those in stratum 1. This correlation was determined to be 0.895. With this approach hIVIG will be considered superior to placebo if either of the two hypotheses is rejected.
Participants will be randomized to a single infusion of an hIVIG product or placebo in a 1:1 allocation. Randomization will be stratified by study site pharmacy and the two SOC strata.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 820
- Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition.
- Positive test for SARS-CoV-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). Tests may include an institutional-based nucleic acid amplification test (NAAT), or any protocol-approved rapid test.
- Within ≤5 days from symptom onset, if symptomatic from current SARS-CoV-2 infection.
- Agrees to not participate in another clinical trial for the treatment or management of SARS-CoV-2 infection through Day 7, or until hospitalized or significant disease progression if prior to Day 7 (defined by ordinal category 4 or 5).
- Participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through Day 28.
Ongoing immunosuppressive condition or immunosuppressive treatment, includes:
- Steroids equivalent to prednisone > 10 mg/day for at least the last 28 days
- Rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy
- Antirejection medicine after solid organ or stem cell transplantation
- Cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months
- Primary or acquired severe B- or T-lymphocyte immune dysfunction
- HIV infection
- Splenectomy or functional asplenia
-
Asymptomatic and had prior symptoms from the current infection that have now resolved (for >24 hours).
-
Asymptomatic and has received a vaccination for COVID-19 (≥1 dose).
-
Undergoing evaluation for possible admission to hospital for medical management (this does not include evaluation of possible hospitalization for public health purposes).
-
Evidence of pneumonia and/or hypoxia due to COVID-19 (NOTE: chest imaging is not required, but if available it should not show new infiltrates suggestive of pneumonia; hypoxia is defined by new oxygen supplementation or increase above pre-illness level).
-
Prior receipt of immunoglobulin product or passive immune therapy for SARS-CoV-2 in the past 90 days (i.e., convalescent plasma, SARS-CoV-2 monoclonal antibodies, or any IVIG).
-
Any of the following thrombotic or procoagulant conditions or disorders:
- acute coronary syndrome, cerebrovascular syndrome, pulmonary embolism, or deep venous thrombosis within 28 days of randomization.
- prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antiphospholipid syndrome, or a deficiency in antithrombin III, protein C, or protein S.
-
History of hypersensitivity to blood, plasma or IVIG excipients.
-
Known immunoglobulin A (IgA) deficiency or anti-IgA antibodies.
-
In the opinion of the investigator, any condition for which participation would not be in the best interest of the participant or that could prevent or confound protocol assessments.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Group Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) Participants in this group will receive the investigational treatment in addition to standard of care. Placebo Group Placebo Participants in this group will receive a placebo in addition to standard of care.
- Primary Outcome Measures
Name Time Method Clinical Status 7 days The primary outcome is to compare the safety and efficacy of a single infusion of hIVIG versus placebo on clinical status after seven days. Outcome will be reported as the percent of participants who fall into each of 5 clinical status categories as defined below.
1. Asymptomatic and no limitations in usual activity due to COVID-19
2. Mild COVID-19 illness or minor limitations to usual activity
3. Moderate COVID-19 illness and with major limitations to usual activity
4. Severe COVID-19 or serious disease manifestation from COVID-19
5. Critical illness from COVID-19 or Death
- Secondary Outcome Measures
Name Time Method All-cause mortality through 28 days. 28 days Outcome reported as the percent of participants who expire for any reason by day 28 post treatment.
Ordinal Scale Distribution 4, 14, 28 days Outcome will be reported as the percent of participants who fall into each of 5 clinical status categories as defined below at days 4, 14, and 28 following treatment.
1. Asymptomatic and no limitations in usual activity due to COVID-19
2. Mild COVID-19 illness or minor limitations to usual activity
3. Moderate COVID-19 illness and with major limitations to usual activity
4. Severe COVID-19 or serious disease manifestation from COVID-19
5. Critical illness from COVID-19 or DeathWorst Status Through 28 Days 28 days Outcome is reported as the number of participants who experience each of the following categories as their worst respiratory status through 28 days, including: a) no respiratory symptoms, b) upper respiratory symptoms, c) lower respiratory symptoms without hypoxia, c) hypoxia requiring conventional oxygen supplementation by nasal canula, d) respiratory failure requiring high-flow oxygen delivery device or non-invasive ventilation, or e) respiratory failure requiring mechanical ventilation or extra-corporeal membrane oxygenation (ECMO).
Significant Disease Progression 28 days Outcome is reported as the number of participants with significant disease progression through 28 days, which is defined by fulfilling criteria for category 4 or 5 on the ordinal scale using a time to event analysis.
Disease Progression Through 7 Days 7 days Outcome is reported as the proportion of participants with any disease progression at Day 7, using a sliding dichotomous scale progression defined by a categorization on the ordinal scale that is worse than the status at entry.
Significant Disease Progression Through 7 Days 7 days Outcome is reported as the proportion of participants who progress to categories 3-5 on the clinical ordinal scale at Day 7 among participants in categories 1 or 2 of the ordinal scale at entry.
Activity Limitations at Follow-up 7, 14, 28 days Outcome is reported as the percent of participants who attain their pre-COVID health status without limitations in usual activity (defined as category 1 on the ordinal scale) at Day 7, 14, and 28.
Change in Viral Burden from Serum Antigen 7 days Outcome is reported as the change between Day 0 and Day 7 in viral burden as determined by serum antigen levels from nasal and saliva specimens.
Change in Viral Burden from PCR 7 days Outcome is reported as the change between Day 0 and Day 7 in viral burden as determined by polymerase chain reaction (PCR) from nasal and saliva specimens.
Change in SARS-CoV-2 Antibody Concentration 7 days Outcome is reported as the change in SARS-CoV-2 antibody levels between Day 0 and Day 7, including subclasses and neutralizing titers.
Additional COVID-19 Treatment 28 days Outcome is reported as the number of patients starting other treatments targeting COVID-19 through 28 days post treatment.
All-cause hospitalization or death through 28 days. 28 days Outcome reported as the percent of participants who are hospitalized or who expire for any reason by day 28 post treatment.
Healthcare Utilization at Follow-up 28 days Outcome is reported as the percent of participants who had health care engagement for the purposes of medical evaluation and/or management of COVID-19 illness (e.g., via telehealth, clinic, urgent care, emergency room, or hospitalization) at 28 days follow-up.
Disease Progression at Follow-up 7, 14, 28 days Outcome is reported as the percent of participants who experience severe disease progression during follow-up, defined by the worst health status achieved on the clinical ordinal scale at any point by Day 7, 14, and 28.
Hypoxemia Through Day 7 7 days Outcome is reported as the mean oxygen saturation (percentage) level in each group at 7 days.
Trial Locations
- Locations (51)
Siriraj Hospital (Site 613-002)
🇹🇭Bangkok Noi, Bangkok, Thailand
San Francisco VAMC (Site 074-002)
🇺🇸San Francisco, California, United States
MedStar Health Research Institute
🇺🇸Washington, District of Columbia, United States
Washington DC Veterans Affairs Medical Center
🇺🇸Washington, District of Columbia, United States
University of Maryland Medical System
🇺🇸Baltimore, Maryland, United States
Henry Ford Health System Site (014-001)
🇺🇸Detroit, Michigan, United States
Infusion Associates
🇺🇸Grand Rapids, Michigan, United States
Mount Sinai Beth Israel Hospital
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Hendrick Medical Center
🇺🇸Abilene, Texas, United States
CHRISTUS Spohn Shoreline Hospital
🇺🇸Corpus Christi, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Carilion Medical Center (Site 080-018)
🇺🇸Roanoke, Virginia, United States
Swedish Hospital First Hill
🇺🇸Seattle, Washington, United States
Instituto Medico Platense
🇦🇷La Plata, Buenos Aires, Argentina
Hospital General de Agudos JM Ramos Mejia
🇦🇷Buenos Aires, Argentina
St. Vincent's Hospital
🇦🇺Sydney, New South Wales, Australia
Odense University Hospital
🇩🇰Odense, C, Denmark
Aarhus Universitetshospital, Skejby
🇩🇰Aarhus, N, Denmark
Department of Infectious Diseases
🇩🇰Aalborg, Denmark
Rigshospitalet, CHIP
🇩🇰Copenhagen, Denmark
Bispebjerg Hospital
🇩🇰Copenhagen, Denmark
Herlev/Gentofte Hospital
🇩🇰Hellerup, Denmark
Hvidovre University Hospital, Department of Infectious Diseases
🇩🇰Hvidovre, Denmark
Kolding Sygehus
🇩🇰Kolding, Denmark
Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital
🇬🇷Athens, Attica, Greece
3rd Dept of Medicine, Medical School
🇬🇷Athens, Attica, Greece
Laiko Athens General Hospital
🇬🇷Athens, Attica, Greece
Department of Clinical Therapeutics of Alexandra Hospital
🇬🇷Athens, Attica, Greece
4th Department of Internal Medicine
🇬🇷Athens, Attica, Greece
All India Institute of Medical Sciences (AIIMS)
🇮🇳Jodhpur, Rajasthan, India
Postgraduate Institute of Medical Education and Research (PGIMER)
🇮🇳Chandigarh, India
Hospital General Dr. Manuel Gea Gonzáles
🇲🇽Mexico City, Cdmx, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
🇲🇽Mexico City, Cdmx, Mexico
Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas
🇲🇽Mexico City, Cdmx, Mexico
CHRISTUS Centro de Excelencia en Investigacion (Obispado)
🇲🇽Monterrey, NL, Mexico
Hospital General Dr. Aurelio Valdivieso
🇲🇽Oaxaca City, OA, Mexico
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
CAP Can Bou
🇪🇸Castelldefels, Barcelona, Spain
CAP El Maresme
🇪🇸Mataro, Barcelona, Spain
CAP Corbera
🇪🇸Barcelona, Spain
Chulalongkorn University and The HIV-NAT
🇹🇭Pathum Wan, Bangkok, Thailand
Khon Kaen University, Srinagarind Hospital (Site 613-003)
🇹🇭Khon Kaen, Thailand
Bamrasnaradura Infections Diseases Institute (613-007)
🇹🇭Nonthaburi, Thailand
MRC/UVRI & LSHTM Uganda Research Unit
🇺🇬Entebbe, Uganda
Joint Clinical Research Center (JCRC)
🇺🇬Kampala, Uganda
St. Francis Hospital, Nsambya
🇺🇬Kampala, Uganda
Lira Regional Referral Hospital
🇺🇬Lira, Uganda
Masaka Regional Referral Hospital
🇺🇬Masaka, Uganda
University College London Hospitals
🇬🇧London, United Kingdom
Royal Victoria Infirmary
🇬🇧Newcastle upon Tyne, United Kingdom